Navigation Links
VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer
Date:1/18/2008

SAN JOSE, Calif., Jan. 18 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS), a leading provider of medical devices for the minimally invasive treatment of venous reflux disease, today announced the appointment of Peter Osborne as Chief Financial Officer and Vice President of Finance and Administration.

Mr. Osborne joins VNUS with over 25 years of finance experience in various senior leadership roles. Mr. Osborne had served as the Company's Interim CFO since October 1, 2007. Prior to VNUS, he held various finance leadership and management roles at Sanmina-SCI, Mercury Interactive/HP, Optillion AB, Neopolitan Networks and WorldChain. Mr. Osborne is a former audit partner of Deloitte & Touche. He is a CPA and holds a Bachelor of Commerce and BS (Honors) Operations Research degrees from the University of Cape Town, South Africa.

VNUS President and Chief Executive Officer Brian Farley stated, "Peter's broad business experience in financial reporting, financial operations management, business process improvement combined with his experience in corporate transactions will add to the depth of our Senior Management Team as we continue the successful growth of our business."

About VNUS Medical Technologies, Inc.

VNUS is a leading provider of medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that is often the underlying cause of painful varicose veins. VNUS sells the Closure(R) system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to close diseased veins through the application of temperature-controlled RF energy. Approximately 300,000 patients have been treated to date
'/>"/>

SOURCE VNUS Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Hollywood Presbyterian Medical Center Responds to ACLU Lawsuit
2. Former Sufferer of Rare Disease Called Musicogenic Epilepsy Thanks LIJ Medical Team That Ended Her Seizures and Gave Her Back the Gift of Music
3. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
4. OMI Medical Imaging, Inc. and Affiliated Companies File Chapter 11 Reorganization
5. Dr. Bart Harmon Named Chief Medical Officer for Harris Corporations Healthcare Solutions Business
6. Study Finds Doctors Not Reporting Medical Mistakes
7. University Hospitals Case Medical Center Ophthalmology gets grant for vision-threatening conditions
8. Synergy Life Science Partners Closes $143M Debut Medical Device Fund
9. Physicians Want to Learn From Medical Mistakes But Say Current Error-Reporting Systems are Inadequate
10. Hiemstra Approved to Manufacture Medical Devices in New CER
11. Liberator Medical Holdings Exceeds December Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Robert J. Reilly, Joins Aethon Team, PITTSBURGH,...aethon.com ), the leading developer of mobile robo...nounced that Robert J. Reilly has,joined the compa...icer., Reilly, who was most recently Vice Preside...pecialty Pharmacy Division, brings more than 30,ye...
(Date:7/25/2008)...ce to be presented at Fenway Park ... /PRNewswire/ -- CVS/pharmacy announced today,that...llion in just 21 days,through its annual in-store ... seventh year of the annual fundraising effort whi...ALS research. This year,s fundraiser took,place in...
(Date:7/25/2008)...ng to drop pounds, study finds , , FRIDA...ded Monday morning weigh-ins knows this unalterabl...Now, researchers have some science to back up diet...: Most people do eat more on the weekend, even whe...ulgences can wreak havoc on weight control, either...
(Date:7/25/2008)...re an Olympian, Professional Athlete, Elite Amateu...ed to Know about Hydration to Boost Sports Perform... Marina del Rey, Calif. (V...are heading to Beijing following years of intense ...of capturing an Olympic medal and securing their p...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5
...lic supplements may not help reduce cholesterol or...lic consumed, says a new study//. Several earlier...ower cholesterol. However, researchers at Stanford...different garlic supplements on nearly 200 adults ...
...vehicles whiz past E.M. Bypass on the city's easte...left indicates the Kolkata Municipal Corporation's... Animals (PFA). It is here that the adage every ...ling pound aims to restore the mental and physical...
...earchers in Philadelphia have found a ground break...brought them to be able to trigger the Epstein-Bar...ntify patients whose infections can then be manipu...at this strategy could actually offer a novel way ...
... annual report for the year 2006 of the Internatio...to UN), suggests that abuse of prescriptions drugs...obe. The abuse of prescription drugs surpasses ...asy, cocaine and heroine in parts of Europe, Afric...
Other Medicine News:Health News:An Anti-rabies Campaign With Bite 2Health News:An Anti-rabies Campaign With Bite 3Health News:Philadelphia Researchers Found A Novel Way To Fight Several Kind of Cancers 2Health News:Philadelphia Researchers Found A Novel Way To Fight Several Kind of Cancers 3
(Date:7/24/2008)...Support Prognostic Value of Circulating Tumor Cell...rnational, prospective,clinical trial found the nu... indicator of progression-free and overall surviva...ording to a report published in the July 1,issue o...onducted in the US, the Netherlands, and the Unite...
(Date:7/24/2008)...AIN VIEW, Calif., July 24 /...nounced today that it has initiated,its second Pha...ine).,AZ-004 is an inhalation product candidate be... in patients with schizophrenia or bipolar disorde...and rapid pharmacokinetic,(PK) properties resultin...
(Date:7/24/2008)...New JIT Enrollment Program Speeds Oncology Patient...ech, Inc., a Research Management,Organization (RMO...,companies to provide research and site management...-in-Time (JIT) enrollment strategy. The new,trials...ular Non-Hodgkin,s,Lymphoma, Metastatic Breast Can...
(Date:7/24/2008)...A ANTIPOLIS, France, July 24 /PRNewswire-FirstCall...ced the top-line results from the 52-week,open lab...he completion of,the 301 phase 3 study for naproxc...ndings and efficacy was maintained for the one-yea...ts, global assessment scale. In,addition, the resu...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 1Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 5Citrate appears to control buckyball clumping but environmental concerns remain 4478 1Citrate appears to control buckyball clumping but environmental concerns remain 4478 2Citrate appears to control buckyball clumping but environmental concerns remain 4478 3Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 1Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 2Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 3Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 1Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 2
...NGTON--(BUSINESS WIRE)--May 22, 2007 - Alequel(TM)...tion, may be an,effective treatment for moderate-t...going double-blind, placebo controlled Phase II,st...nduced good,clinical remissions and improved patie...researchers from Hebrew University-Hadassah,Medica...
... results report no new stent thrombosis after two ...s., and BARCELONA, Spain, May 22, 2007,/PRNewswire...,announced four-year follow-up data from its TAXUS... safety and efficacy benefits,associated with a mo...(TM) paclitaxel-eluting stent system -- which is n...
Other Medicine Technology:Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 2Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 3Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3
Desmarrres Lid Retractor, round serrated handle, polished finish, overall length 130 mm.
The Storz Protege is an anterior segment unit only.
The CV-12000 provides the surgeon with all the options to perform today's newest techniques.
Phaco-emulsification systems CV series
Medicine Products: